https://www.selleckchem.com/Caspase.html
38, CI 1.27-1.5, earlier major bleeding (HR 1.58, Cl 1.09-2.3, COPD (HR 1.28, CI 1.04-1.6 and previous stroke (HR 1.28, Cl 1.03-1.58) or transient ischemic attack (TIA) (HR 1.33, Cl 1.01-1.76). Prior warfarin treatment was protective (HR 0.67, CI 0.58-0.78). This real world cohort shows a high bleeding rate especially among the elderly and in patients with previous major bleeding, COPD and previous stroke or TIA. This should be considered when deciding on treatment duration and NOAC dose in these patients. The psychosocial risk assessment
Like
Comment
Share
